Entinostat (SNDX-275) for the treatment of non-small cell lung cancer

Bibliography

• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. Ca Cancer J Clin 2014;64(1):9–29
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center M, et al. Global Cancer Statistics. Ca Cancer J Clin 2011;61(2):69–90
   PubMed Web of Science ®Google Scholar
• Chen VW, Ruiz BA, Hsieh MC, et al. Analysis of stage and clinical/prognostic factors for lung cancer from SEER registries: AJCC staging and collaborative stage data collection system. Cancer 2014;120(Suppl 23):3781–92
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP, et al. Eastern cooperative oncology group. comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346(2):92–8
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144(5):646–74
   PubMed Web of Science ®Google Scholar
• Mok T, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947–57
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre open-label randomised phase 3 trial. Lancet Oncol 2012;13:239–46
   PubMed Web of Science ®Google Scholar
• Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3327–34
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368(25):2385–94
   PubMed Web of Science ®Google Scholar
• Bowman R, Yang I, Semmler A, Fong K. Epigenetics of lung cancer. Respirology 2006;11(4):355–65
   PubMed Web of Science ®Google Scholar
• Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004;4(2):143–53
   PubMed Web of Science ®Google Scholar
• Geutjes EJ, Bajpe PK, Bernards R. Targeting the epigenome for treatment of cancer. Oncogene 2012;31(34):3827–44
   PubMed Web of Science ®Google Scholar
• Liu SV, Fabbri M, Gitlitz BJ, Laird-Offringa IA. Epigenetic therapy in lung cancer. Front Oncol 2013;3(135):1–8
   Google Scholar
• Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000;403(6765):41–5
   PubMed Web of Science ®Google Scholar
• Clayton AL, Hazzalin CA, Mahadevan LC. Enhanced histone acetylation and transcription: a dynamic perspective. Mol Cell 2006;23(3):289–96
   PubMed Web of Science ®Google Scholar
• Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007;26(37):5541–52
   PubMed Web of Science ®Google Scholar
• Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res 2011;21(3):381–95
   PubMed Web of Science ®Google Scholar
• Barneda-Zahonero B, Parra M. Histone deacetylases and cancer. Mol Oncol 2012;6(6):579–89
   PubMed Web of Science ®Google Scholar
• Miller T, Witter D, Belvedere S. Histone deacetylase inhibitors. J Med Chem 2003;46(24):5097–116
   PubMed Web of Science ®Google Scholar
• Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25(21):3109–15
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye R, Prince HM, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011;117(22):5827–34
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009;27(32):5410–17
   PubMed Web of Science ®Google Scholar
• Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007;109(1):31–9
   PubMed Web of Science ®Google Scholar
• Belani C, Ramalingam S, Kalemkerian G, et al. Randomized, double-blind phase II/III study of first-line paclitaxel (P) plus carboplatin (C) in combination with vorinostat or placebo in patients with advanced non-small-cell lung cancer. Eur J Cancer 2009;7(suppl):507, abstr O-9007
   Google Scholar
• Saito A, Yamashita T, Mariko Y, et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 1999;96(8):4592–7
   PubMed Web of Science ®Google Scholar
• Acharya MR, Sparreboom A, Sausville EA, et al. Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor. Cancer Chemother Pharmacol 2006;57(3):275–81
   PubMed Web of Science ®Google Scholar
• Ryan QC, Headlee D, Acharya M, et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 2005;23(17):3912–22
   PubMed Web of Science ®Google Scholar
• Gojo I, Jiemiit A, Trepel J, et al. Phase 1 and pharmacologic study of MS275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 2007;109(7):2781–90
   PubMed Web of Science ®Google Scholar
• Gore L, Rothenberg ML, O’bryant CL, et al. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res 2008;14(14):4517–25
   PubMed Web of Science ®Google Scholar
• Kummar S, Gutierrez M, Gardner ER, et al. Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin Cancer Res 2007;13(18 Pt 1):5411–17
   PubMed Web of Science ®Google Scholar
• Knipstein J, Gore L. Entinostat for treatment of solid tumors and hematologic malignancies. Expert Opin Investig Drugs 2011;20(10):1455–67
   PubMed Web of Science ®Google Scholar
• Hooker JM, Kim SW, Alexoff D, et al. Histone deacetylase inhibitor, MS-275, exhibits poor brain penetration: PK studies of [C]MS-275 using Positron Emission Tomography. ACS Chem Neurosci 2010;1(1):65–73
   PubMed Web of Science ®Google Scholar
• Acharya MR, Karp JE, Sausville EA, et al. Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer. Invest New Drugs 2006;24(5):367–75
   PubMed Web of Science ®Google Scholar
• Hess-stumpp H, Bracker TU, Henderson D, Politz O. MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agent. Int J Biochem Cell Biol 2007;39(7-8):1388–405
   PubMed Web of Science ®Google Scholar
• Rosato RR, Almenara JA, Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 2003;63(13):3637–45
   PubMed Web of Science ®Google Scholar
• Lee B, Park S, Kim J, et al. MS-275, A Histone deacetylase inhibitor, selectively induces transforming growth factor B Type II receptor expression in human breast cancer cells. Cancer Res 2001;61(3):931–4
   PubMed Web of Science ®Google Scholar
• Lucas DM, Davis ME, Parthun MR, et al. The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia 2004;18(7):1207–14
   PubMed Web of Science ®Google Scholar
• Nebbioso A, Clarke N, Voltz E, et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nature Med 2005;11(1):77–84
   PubMed Web of Science ®Google Scholar
• Belinsky S, Grimes M, Picchi M, et al. Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model. Cancer Res 2011;71(2):454–62
   PubMed Web of Science ®Google Scholar
• Jaboin J, Wild J, Hamidi H, et al. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res 2002;62(21):6108–15
   PubMed Web of Science ®Google Scholar
• Lee CK, Wang S, Huang X, et al. HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells. Cancer Lett 2010;296(2):233–40
   PubMed Web of Science ®Google Scholar
• Witta SE, Gemmill RM, Hirsch FR, et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 2006;66(2):944–50
   PubMed Web of Science ®Google Scholar
• Witta S, Chan D, Girard L, et al. Effects of entinostat on resistance to cetuximab and EGFR TKIs in non-small cell lung cancer. J Clin Oncol 2012;30(Suppl):abstr e18077
   Google Scholar
• Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5(9):769–84
   PubMed Web of Science ®Google Scholar
• Cameron EE, Bachman KE, Myöhänen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999;21(1):103–7
   PubMed Web of Science ®Google Scholar
• Belinsky SA, Klinge DM, Stidley CA, et al. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res 2003;63(21):7089–93
   PubMed Web of Science ®Google Scholar
• Tellez CS, Grimes MJ, Picchi MA, et al. SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome. Int J Cancer 2014;135(9):2223–31
   PubMed Web of Science ®Google Scholar
• Vendetti FP, Topper M, Huang P, et al. Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer. Oncotarget 2015;6(1):56–70
   PubMedGoogle Scholar
• National Cancer Institute. Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Online Available from: https://clinicaltrials.gov/ct2/show/NCT01935947 [ Last accesed 30 January 2015]
   Google Scholar
• Konduri K, Spira A, Jotte R, et al. Results from a phase I safety lead-in study investigating the combination of erlotinib and the histone deacetylase inhibitor entinostat in patients with advanced NSCLC. J Clin Oncol 2009;27(suppl):abstr e14545
   Google Scholar
• Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139(5):871–90
   PubMed Web of Science ®Google Scholar
• Yauch RL, Januario T, Eberhard DA, et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 2005;11(24 Pt 1):8686–98
   PubMed Web of Science ®Google Scholar
• Thomson S, Buck E, Petti F, et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 2005;65(20):9455–62
   PubMed Web of Science ®Google Scholar
• Witta SE, Jotte RM, Konduri K, et al. Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. J Clin Oncol 2012;30(18):2248–55
   PubMed Web of Science ®Google Scholar
• Juergens RA, Wrangle J, Vendetti FP, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov 2011;1(7):598–607
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095–103
   PubMed Web of Science ®Google Scholar
• Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527–1
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353(2):123–32
   PubMed Web of Science ®Google Scholar
• Brock MV, Hooker CM, Ota-machida E, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008;358(11):1118–28
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Azacitidine and entinostat in treating patients with newly diagnosed stage IA-IIIA non-small lung cancer undergoing surgery. Clinical Trials.gov [Internet]. Bethesda, MD; National Library of Medicine (US) 2000. Online Available from: https://clinicaltrials.gov/ct2/show/NCT01886573?term=ENTINOSTAT&rank=8&submit_fld_opt= [Last accessed 12 May 2015]
   Google Scholar
• Institute NC. A Phase 2 exploratory study of erlotinib and SNDX-275 in patients with non-small cell lung carcinoma who are progressing on erlotinib. ClinicalTrials.gov [Internet]. Bethesda, MD; National Library of Medicine (US) [ Online 2000. Available from: https://clinicaltrials.gov/ct2/show/study/NCT00750698 [Last accessed 12 May 2015]
   Google Scholar
• Brahmer JR, Horn L, Scott A, et al. Survival and long-term follow-up of the phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC). Program and abstracts of the 2013 American Society of Clinical Oncology Annual Meeting; 31-June 4 May 2013; Chicago, Illinois. Abstract 8030
   Google Scholar
• Bristol-Myers Squibb. Study of BMS-936558 (Nivolumab) compared to docetaxel in previously treated metastatic non-squamous NSCLC (CheckMate 057). ClinicalTrials.gov [Internet]. Bethesda, MD; National Library of Medicine (US) 2000. Online Available from: https://clinicaltrials.gov/ct2/show/NCT01673867?term=nivolumab&rank=19 [Last accessed 30 January 2015]
   Google Scholar
• Sidney Kimmel Comprehensive Cancer Center. Phase II Anti-PD1 Epigenetic Priming Study in NSCLC. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Online Available from: https://clinicaltrials.gov/ct2/show/NCT01928576 [ Cited 30 January 2015]
   Google Scholar
• Fraczek J, Vanhaecke T, Rogiers V. Toxicological and metabolic considerations for histone deacetylase inhibitors. Expert Opin Drug Metab Toxicol 2013;9(4):441–57
   PubMed Web of Science ®Google Scholar